Literature DB >> 26902923

The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031.

David C Whiteman1, Adele C Green2, Catherine M Olsen3.   

Abstract

New melanoma therapies are being developed rapidly, complementing prevention and detection strategies for disease control. Estimating the future burden of melanoma is necessary for deciding how best to deploy limited resources to achieve effective melanoma control. Using three decades of cancer registry data (1982-2011) from six populations with moderate to high melanoma incidence (US whites and the populations of the United Kingdom, Sweden, Norway, Australia, New Zealand), we applied age-period-cohort models to describe current trends and project future incidence rates and numbers of melanomas out to 2031. Between 1982 and 2011, melanoma rates in US whites, and the populations of the United Kingdom, Sweden, and Norway increased at more than 3% annually and are projected to continue rising until at least 2022. Melanoma incidence in Australia has been declining since 2005 (-0.7% per year), and melanoma incidence in New Zealand is increasing but is projected to decline soon. The numbers of new melanoma cases will rise in all six populations because of aging populations and high age-specific rates in the elderly. In US whites, annual new cases will rise from around 70,000 in 2007-2011 to 116,000 in 2026-2031, with 79% of the increase attributable to rising age-specific rates and 21% to population growth and aging. The continued increases in case numbers in all six populations through 2031 will increase the challenges of melanoma control.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26902923     DOI: 10.1016/j.jid.2016.01.035

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  130 in total

1.  Reliable test of clinicians' mastery in skin cancer diagnostics.

Authors:  Niels Kvorning Ternov; T Vestergaard; L Rosenkrantz Hölmich; K Karmisholt; A L Wagenblast; H Klyver; M Hald; L Schøllhammer; L Konge; A H Chakera
Journal:  Arch Dermatol Res       Date:  2020-06-28       Impact factor: 3.017

2.  A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo.

Authors:  Pamela B Cassidy; Tong Liu; Scott R Florell; Matthew Honeggar; Sancy A Leachman; Kenneth M Boucher; Douglas Grossman
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-05

3.  Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.

Authors:  Barbara Fontanals-Cirera; Dan Hasson; Chiara Vardabasso; Raffaella Di Micco; Praveen Agrawal; Asif Chowdhury; Madeleine Gantz; Ana de Pablos-Aragoneses; Ari Morgenstern; Pamela Wu; Dan Filipescu; David Valle-Garcia; Farbod Darvishian; Jae-Seok Roe; Michael A Davies; Christopher R Vakoc; Eva Hernando; Emily Bernstein
Journal:  Mol Cell       Date:  2017-11-16       Impact factor: 17.970

4.  The incidence of skin melanoma in Gran Canaria (Canary Islands, Spain) is lower than expected in Southern Europe despite high-risk environmental conditions: an island-wide cross-sectional study.

Authors:  Mercè Grau-Pérez; Gregorio Carretero; Pablo Almeida; Elena Castro-González; María Del Pilar de-la-Rosa-Del-Rey; Jesús María González-Martín; Leopoldo Borrego
Journal:  Cancer Causes Control       Date:  2021-03-01       Impact factor: 2.506

5.  Divergence of cAMP signalling pathways mediating augmented nucleotide excision repair and pigment induction in melanocytes.

Authors:  Erin M Wolf Horrell; Stuart G Jarrett; Katharine M Carter; John A D'Orazio
Journal:  Exp Dermatol       Date:  2017-04-21       Impact factor: 3.960

Review 6.  [Photocarcinogenesis-molecular mechanisms and practical relevance].

Authors:  M Mengoni; T Tüting; E Gaffal
Journal:  Hautarzt       Date:  2021-01       Impact factor: 0.751

Review 7.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

8.  Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.

Authors:  Michael R Sargen; Donato Calista; David E Elder; Daniela Massi; Emily Y Chu; Míriam Potrony; Ruth M Pfeiffer; Cristina Carrera; Paula Aguilera; Llucia Alos; Susana Puig; Rosalie Elenitsas; Xiaohong R Yang; Margaret A Tucker; Maria Teresa Landi; Alisa M Goldstein
Journal:  J Am Acad Dermatol       Date:  2020-04-10       Impact factor: 11.527

Review 9.  The discovery and development of binimetinib for the treatment of melanoma.

Authors:  Brian Tran; Mark S Cohen
Journal:  Expert Opin Drug Discov       Date:  2020-04-04       Impact factor: 6.098

10.  Skin Cancer-The Importance of Prevention.

Authors:  Eleni Linos; Kenneth A Katz; Graham A Colditz
Journal:  JAMA Intern Med       Date:  2016-10-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.